gutflix
GI learning, personalised

Summary

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Alessandra Oortwijn

UEG Week Copenhagen 2023 | Poster

IBD

October 16, 2023

Post hoc analysis of the SELECTION trial identified baseline characteristics associated with achieving 6-month corticosteroid-free remission in ulcerative colitis patients treated with filgotinib.

KEY POINTS

- Among patients receiving corticosteroids at baseline, 27.2% of those treated with filgotinib 200 mg achieved corticosteroid-free remission at week 58 compared with 6.4% receiving placebo.
- A baseline Mayo endoscopic subscore of 2 versus 3 was associated with significantly increased odds of 6-month corticosteroid-free remission in both the filgotinib 200 mg group (OR 5.229, p=0.001) and the 100 mg group (OR 3.741, p=0.048).
- In the filgotinib 200 mg group, male sex (OR 0.325, p=0.034), former versus current smoker status (OR 0.078, p=0.028), and prior biologic exposure (OR 0.231, p=0.004) were associated with significantly reduced odds of achieving corticosteroid-free remission.
- Most baseline characteristics including age, body mass index, disease duration, inflammatory markers, Mayo Clinic Score, and concomitant medications had no statistically significant effect on achieving corticosteroid-free remission with filgotinib 200 mg treatment.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/45ca50cc-743c-11ee-8f00-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.